N
Nima Aghdam
Researcher at Georgetown University
Publications - 42
Citations - 516
Nima Aghdam is an academic researcher from Georgetown University. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 8, co-authored 29 publications receiving 327 citations. Previous affiliations of Nima Aghdam include University of Washington & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer.
Amar U. Kishan,Audrey Dang,Alan J. Katz,Constantine Mantz,Sean P. Collins,Nima Aghdam,Fang-I Chu,Irving D. Kaplan,Limor Appelbaum,Donald B. Fuller,Robert M. Meier,D. Andrew Loblaw,Patrick Cheung,Huong T. Pham,Narek Shaverdian,Narek Shaverdian,Naomi Jiang,Ye Yuan,Hilary P. Bagshaw,Nicolas D. Prionas,Mark K. Buyyounouski,Daniel E. Spratt,Patrick W. Linson,R.L. Hong,Nicholas G. Nickols,Michael L. Steinberg,Patrick A. Kupelian,Christopher R. King +27 more
TL;DR: The data suggest that stereotactic body radiotherapy is an appropriate definitive treatment modality for low-risk and intermediate-risk prostate cancer, and is associated with low rates of severe toxic events and high rates of biochemical control.
Journal ArticleDOI
High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations.
Bryan T. Mott,Richard T. Eastman,Rajarshi Guha,Katy S. Sherlach,Amila Siriwardana,Paul Shinn,Crystal McKnight,Sam Michael,Norinne Lacerda-Queiroz,Paresma R. Patel,Pwint Khine,Hongmao Sun,Monica Kasbekar,Nima Aghdam,Nima Aghdam,Shaun D. Fontaine,Dongbo Liu,Tim Mierzwa,Lesley Mathews-Griner,Marc Ferrer,Adam R. Renslo,James Inglese,Jing Yuan,Paul D. Roepe,Xin-zhuan Su,Craig J. Thomas +25 more
TL;DR: A large collection of approved and investigational drugs are screened, tested 13,910 drug pairs, and a myriad of new classes of positively interacting drug pairings were discovered, highlighting important targets and pathways and providing promising leads for clinically actionable antimalarial therapy.
Journal ArticleDOI
Long-term outcomes of stereotactic body radiation therapy (SBRT) with fiducial tracking for inoperable stage I non-small cell lung cancer (NSCLC)
Jonathan W. Lischalk,Stephanie Woo,Shaan Kataria,Nima Aghdam,Ima Paydar,Michael C. Repka,Eric D. Anderson,Brian T. Collins +7 more
TL;DR: Despite reduced treatment margins and lack of patient immobilization, S BRT with fiducial-based tumor tracking achieves clinically comparable long-term outcomes to other linac-based SBRT approaches.
Journal ArticleDOI
Erectile Function after Stereotactic Body Radiotherapy for Localized Prostate Cancer
Robert T. Dess,Holly E. Hartman,Nima Aghdam,William C. Jackson,Payal D. Soni,Ahmed E. Abugharib,Simeng Suy,Neil Desai,Zachary S. Zumsteg,Rohit Mehra,Todd M. Morgan,Felix Y. Feng,Daniel A. Hamstra,Matthew J. Schipper,Sean P. Collins,Daniel E. Spratt +15 more
TL;DR: To elucidate the functional erection rate after prostate stereotactic body radiotherapy (SBRT) and to develop a comprehensive prognostic model of outcomes after treatment.
Journal ArticleDOI
Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients.
Ritchell van Dams,Naomi Y. Jiang,Donald B. Fuller,Andrew Loblaw,Tommy Jiang,Alan J. Katz,Sean P. Collins,Nima Aghdam,Simeng Suy,Kevin L. Stephans,Ye Yuan,Nicholas G. Nickols,Vedang Murthy,Tejshri P. Telkhade,Patrick A. Kupelian,Michael L. Steinberg,Tahmineh Romero,Amar U. Kishan +17 more
TL;DR: Data support a favorable toxicity and efficacy profile for SBRT for HRPCa in a consortium of seven institutional phase II trials and prospective registries and further prospective studies are needed to evaluate the optimal dose and target volume.